Shanghai Pharmaceuticals Holding Co., Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Shanghai Pharmaceuticals Holding Co., Ltd
While China’s increasingly inward-looking macro economic policies and other regulatory hurdles are likely to impact smaller players, positive biopharma policy moves in competing hub contenders including Shanghai and the Greater Bay Area also offer attractive opportunities.
Plus deals involving Zai Lab/Karuna, Zai Lab/Blueprint, Lotus/PharmaMar, Nippon Shinyaku/Dynacure, Alphamab/Ascletis, Aptose/Hanmi, Shanghai Pharmaceuticals/HUYABIO, KoBioLabs/SPH Sine, CURACLE/ Théa Open Innovation, Signet/XtalPi, Curi Bio/NEXEL, CANbridge/Scriptr and Ligand/CRDC.
I-Mab sets commercial plans with Sinopharm for felzartamab in multiple myeloma. Legochem and Antengene team up on antibody-drug conjugates, Luoxin licenses respiratory drug from Marinomed.
A concerted effort to mobilize the pharma industry, research organizations and state-backed healthcare venture capital firms is under way in Shanghai.
- Medical Devices
- OTC, Consumer
- Other Names / Subsidiaries
- Beijing Kyuan Pharmaceutical Co., Ltd.
- Cardinal Health China
- Techpool Bio-pharma Co., Ltd
- Shanghai Pharmaceutical Group Co., Ltd.